ACTL6A and familial pancreatic carcinoma: Regarding ACTL6A, we found that ACTL6A expression might significantly affect the survival time of patients with pancreatic cancer (HR, 1.88; 95% CI, 1.21 to 2.94), brain lower grade glioma (HR, 1.85; 95% CI, 1.13 to 3.01), lung adenocarcinoma (HR, 1.59; 95% CI, 1.04 to 2.43), and sarcoma (HR, 1.61; 95% CI, 1.06 to 2.46) (Fig 4A).